Literature DB >> 22035519

Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs.

Yunyan Kuang1, Kumudha Balakrishnan, Varsha Gandhi, Xiaohua Peng.   

Abstract

The major concern for anticancer chemotherapeutic agents is the host toxicity. The development of anticancer prodrugs targeting the unique biochemical alterations in cancer cells is an attractive approach to achieve therapeutic activity and selectivity. We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high level of reactive oxygen species (ROS) found in cancer cells to release the active chemotherapy agent. The activation mechanism was determined by NMR analysis. The activity and selectivity of these prodrugs toward ROS was determined by measuring DNA interstrand cross-links and/or DNA alkylations. These compounds showed 60-90% inhibition toward various cancer cells, while normal lymphocytes were not affected. To the best of our knowledge, this is the first example of H(2)O(2)-activated anticancer prodrugs.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035519      PMCID: PMC3265938          DOI: 10.1021/ja2073824

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  30 in total

1.  Development of highly selective and sensitive probes for hydrogen.

Authors:  Lee-Chiang Lo; Chi-Yuan Chu
Journal:  Chem Commun (Camb)       Date:  2003-11-07       Impact factor: 6.222

2.  Dynamic cross-linking is retained in duplex DNA after multiple exchange of strands.

Authors:  Huan Wang; Steven E Rokita
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

Review 3.  Formation and repair of interstrand cross-links in DNA.

Authors:  David M Noll; Tracey McGregor Mason; Paul S Miller
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

4.  Synthesis and characterization of oligodeoxynucleotides containing formamidopyrimidine lesions and nonhydrolyzable analogues.

Authors:  Kazuhiro Haraguchi; Michael O Delaney; Carissa J Wiederholt; Aruna Sambandam; Zsolt Hantosi; Marc M Greenberg
Journal:  J Am Chem Soc       Date:  2002-04-03       Impact factor: 15.419

5.  Molecular imaging of hydrogen peroxide produced for cell signaling.

Authors:  Evan W Miller; Orapim Tulyathan; Orapim Tulyanthan; Ehud Y Isacoff; Christopher J Chang
Journal:  Nat Chem Biol       Date:  2007-04-01       Impact factor: 15.040

6.  Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.

Authors:  S M Rink; K J Yarema; M S Solomon; L A Paige; B M Tadayoni-Rebek; J M Essigmann; R G Croy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

7.  Oxygen independent DNA interstrand cross-link formation by a nucleotide radical.

Authors:  In Seok Hong; Hui Ding; Marc M Greenberg
Journal:  J Am Chem Soc       Date:  2006-01-18       Impact factor: 15.419

8.  Production of large amounts of hydrogen peroxide by human tumor cells.

Authors:  T P Szatrowski; C F Nathan
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  An ICT-based approach to ratiometric fluorescence imaging of hydrogen peroxide produced in living cells.

Authors:  Duangkhae Srikun; Evan W Miller; Dylan W Domaille; Christopher J Chang
Journal:  J Am Chem Soc       Date:  2008-03-13       Impact factor: 15.419

Review 10.  ROS stress in cancer cells and therapeutic implications.

Authors:  Helene Pelicano; Dennis Carney; Peng Huang
Journal:  Drug Resist Updat       Date:  2004-04       Impact factor: 18.500

View more
  50 in total

1.  ROS-inducible DNA cross-linking agent as a new anticancer prodrug building block.

Authors:  Sheng Cao; Yibin Wang; Xiaohua Peng
Journal:  Chemistry       Date:  2012-02-29       Impact factor: 5.236

Review 2.  Looking beneath the surface to determine what makes DNA damage deleterious.

Authors:  Marc M Greenberg
Journal:  Curr Opin Chem Biol       Date:  2014-04-22       Impact factor: 8.822

3.  Novel oxidatively activated agents modify DNA and are enhanced by ercc1 silencing.

Authors:  Amy R Jones; Tiffany R Bell-Horwath; Guorui Li; Stephanie M Rollmann; Edward J Merino
Journal:  Chem Res Toxicol       Date:  2012-10-22       Impact factor: 3.739

4.  Catalytic enantioselective alkene aminohalogenation/cyclization involving atom transfer.

Authors:  Michael T Bovino; Sherry R Chemler
Journal:  Angew Chem Int Ed Engl       Date:  2012-03-05       Impact factor: 15.336

Review 5.  Prodrug strategies for targeted therapy triggered by reactive oxygen species.

Authors:  Jorge Peiró Cadahía; Viola Previtali; Nikolaj S Troelsen; Mads H Clausen
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

6.  H2O2/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells.

Authors:  Yi Liao; Liping Xu; Siyu Ou; Holly Edwards; Daniel Luedtke; Yubin Ge; Zhihui Qin
Journal:  ACS Med Chem Lett       Date:  2018-06-13       Impact factor: 4.345

Review 7.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

8.  ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.

Authors:  Xiaohua Peng; Varsha Gandhi
Journal:  Ther Deliv       Date:  2012-07

Review 9.  Boron chemicals in diagnosis and therapeutics.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

10.  Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.

Authors:  Shilong Zheng; Shanchun Guo; Qiu Zhong; Changde Zhang; Jiawang Liu; Lin Yang; Qiang Zhang; Guangdi Wang
Journal:  ACS Med Chem Lett       Date:  2018-01-08       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.